Pacific Edge Halts Trading to Launch NZ$24 Million Capital Raise for Medicare Recovery

Pacific Edge Limited has entered a trading halt on its ordinary shares across both the NZX and ASX as it launches a capital raise of up to NZ$24 million. The fundraising effort, effective pre-market open on May 11, 2026, is designed to provide the cancer diagnostics firm with the necessary liquidity to navigate the regulatory path toward regaining US Medicare coverage for its Cxbladder products. The capital raise is structured as an NZ$18 million placement to institutional and select investors, complemented by a retail offer of up to NZ$6 million for eligible New Zealand shareholders.

New shares under the offer are priced at NZ$0.170 per share. This follows a period of significant financial pressure for the Dunedin-based organisation, which saw its share price close at NZ$0.174 on May 8, 2026, after a daily fall of 1.14%. The primary objective of the capital injection is to secure the resources required to achieve test reimbursement and support future growth initiatives. This move comes after a challenging period initiated by a Medicare non-coverage determination that became effective in April 2025, which substantially curtailed the company's revenue-generating capacity in its largest market.

Financial Performance and Revenue Impact

Preliminary unaudited financial results for the fiscal year ending March 31, 2026, highlight the scale of the impact following the loss of Medicare reimbursement. Operating revenue for FY26 fell to NZ$11.5 million, representing a sharp decrease from the NZ$21.8 million recorded in FY25. The reduction in revenue is directly linked to the change in US coverage, which led to a 21.4% reduction in US total laboratory throughput. Total laboratory throughput in the United States reached 18,784 tests in FY26, down from 23,885 tests in the previous fiscal year.

Despite the headwinds in the North American market, Pacific Edge reported some positive momentum in other regions. The company saw an APAC volumes increase of 7.9% during FY26. However, the overall financial position remains strained, with the net loss for FY26 widening to NZ$35.7 million. By the end of March 2026, the company's cash reserves had diminished to NZ$7.8 million.

In response to these conditions, Pacific Edge has focused on aggressive cost management. Total expenses were reduced to NZ$49.3 million in FY26, down from NZ$54.6 million in FY25. These efforts are evident in the company's cash burn trajectory. The average 1H 26 monthly cash burn of NZ$3.3 million was successfully reduced to an average 2H 26 monthly cash burn of NZ$2.4 million.

The Path to Medicare Reinstatement

The future of Pacific Edge remains heavily dependent on the restoration of Medicare coverage for its Cxbladder tests. The company is currently working with the Medicare contractor Novitas to navigate the complex regulatory environment. A significant milestone occurred on February 19, 2026, during a Contractor Advisory Committee meeting hosted by Novitas. The meeting provided an evidence-based mandate for the coverage of urine-based biomarkers, which included the review of publications.